Boehringer set to make E.coli for clinical trials

- Last updated on GMT

Boehringer will make E.coli amongst other HP clinical materials for Molecular Partners
Boehringer will make E.coli amongst other HP clinical materials for Molecular Partners
Molecular Partners has contracted Boehringer Ingelheim to produce a range of highly potent molecules for its clinical pipeline.

Under the deal, Boehringer will manufacture a range of toxic materials including E.coli and other proteins for the DARPin pipeline.

The move the German firm’s recent expansion  of its biomanufacturing facility​ and mammalian contract manufacturing services in Germany.

Simon Sturge, Boehringer’s corporate senior VP of biopharmaceuticals said: “This agreement reflects the strategy of Boehringer Ingelheim and its new brand Boehringer Ingelheim BioXcellence to be dedicated and committed to the development of highly innovative molecule platforms and projects.”

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers